ibrilatazar

Ibrilatazar is a first-in-class oral small-molecule anticancer drug developed by Ability Pharmaceuticals. It is a synthetic derivative of omega-6 polyunsaturated fatty acids and acts as an autophagy inducer through dual mechanisms. Ibrilatazar activates peroxisome proliferator-activated receptor alpha (PPARα) and gamma (PPARγ), leading to overexpression of TRIB3 and subsequent inhibition of the PI3K/Akt/mTOR pathway—a key driver in many cancers. This results in robust autophagic cell death selectively in cancer cells via induction of endoplasmic reticulum stress and unfolded protein response. Ibrilatazar has demonstrated clinical benefit in endometrial cancer and lung cancer trials, with ongoing Phase II studies for metastatic pancreatic cancer. The drug has received orphan drug designation from both the FDA and EMA for pancreatic cancer, biliary cancer, and pediatric neuroblastoma[1][5][7].

Brand names

Ibrilatazar

Other names

α-hydroxylinoleic acid2-hydroxylinoleic acid